ARTICLE | Emerging Company Profile
BioCentury’s 2021 class of emerging cell therapy companies
The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing
February 12, 2022 1:39 AM UTC
Cell therapy start-ups selected for BioCentury’s 2021 class of Emerging Company Profiles are taking on tough challenges — from durability to safety to manufacturing — to bring the modality beyond its toehold in blood cancers, making it more accessible to more patients with more diseases.
At 19 companies, cell therapy start-ups represented the largest single segment (16%) of the 118 companies in BioCentury’s 2021 Emerging Company Profiles. Other major themes included targeted protein degradation, RNA therapeutics, delivery technologies and regulation of gene expression...